Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
Immix Biopharma, Inc. (Nasdaq:IMMX)
Format
PNG
Source
Immix Biopharma, Inc.